A deeper understanding of the structural and functional properties of GPBAR1 and FXR is therefore instrumental for drug design, guiding the development of modulators aimed at generating new therapeutic opportunities for liver pathologies and metabolic diseases, in which these receptors play a pivotal role. This evidence concerns the gene GPBAR1 and metabolic disease.